Hypoxanthine-guanine phosphoribosyltransferase (HGPRT) deficiency, known in its most severe form as Lesch-Nyhan syndrome, is an X-linked hereditary disorder caused by variants in the HPRT1 gene. Alteration of purine metabolism leads to overproduction of uric acid and, depending on residual enzyme activity, neurological and behavioral manifestations of variable severity.
Hypoxanthine-guanine phosphoribosyltransferase deficiency
The HPRT1 gene encodes the enzyme HGPRT, essential in the purine salvage or recycling pathway. Purines, such as hypoxanthine and guanine, are building blocks of DNA and RNA. Under normal conditions, HGPRT allows them to be reused by converting hypoxanthine into inosine monophosphate (IMP) and guanine into guanosine monophosphate (GMP). When pathogenic variants exist in HPRT1, the enzyme may be absent or have reduced activity, completely or partially blocking this metabolic pathway.
As a consequence, un-recycled purines are excessively degraded, leading to an accumulation of uric acid. This causes hyperuricemia, with a risk of crystals in the joints, gout, kidney stones, and urate nephropathy. Neurological and behavioral involvement is characteristic of the more severe forms and is related to altered purine metabolism in the nervous system. Inheritance is X-linked recessive, thus mainly affecting hemizygous males, while carrier females are usually asymptomatic or present mild manifestations. The estimated prevalence of the classic phenotype is approximately 1 in 380,000 newborns.
Symptoms
Lesch-Nyhan syndrome, the classic and most severe form, usually manifests during the first months of life, typically between 3 and 6 months, with psychomotor developmental delay and hypotonia. Hyperuricemia can be observed as orange crystals or "sand" in the diaper. Over time, dystonia, choreoathetosis, spasticity, and motor disability appear. The most distinctive feature is compulsive self-injurious behavior, such as lip or finger biting. There are intermediate forms with milder neurological involvement and without self-injury, and mild forms limited mainly to hyperuricemia, gout, or kidney stones.
Disease management
Management is aimed at preventing complications arising from excess uric acid and treating neurological and behavioral symptoms. Allopurinol is used to reduce uric acid production and decrease the risk of gout, kidney stones, and kidney damage, accompanied by good hydration and nephrological monitoring. However, this treatment does not improve neurological manifestations. The approach requires a multidisciplinary team with neurology, nephrology, rehabilitation, occupational therapy, behavioral support, and protective measures to avoid self-harm injuries.
Genes analyzed
Bibliography
Fu R, Sutcliffe D, Zhao H, et al. Clinical severity in Lesch-Nyhan disease: the role of residual enzyme and compensatory pathways. Mol Genet Metab. 2015 Jan;114(1):55-61.
Jinnah HA. HPRT1 Disorders. 2000 Sep 25 [updated 2020 Aug 6]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
